Achieve Completes Analytical Transfer and First Engineering Batch for Cytisinicline at Adare’s Ohio Facility
Achieve Life Sciences completed analytical method transfer to Adare Pharma Solutions’ Vandalia, Ohio, facility and manufactured its first cytisinicline engineering batch. The partnership secures U.S. supply chain redundancy following tariffs and sets up an NDA resubmission in Q4 2026 ahead of a planned first-half 2027 launch.
1. Operational Milestone
Achieve Life Sciences finalized the analytical method transfer and first cytisinicline engineering batch at Adare Pharma Solutions’ Vandalia, Ohio, plant, validating all testing procedures and preparing for commercial-scale manufacturing.
2. Supply Chain Resilience
The U.S.-based manufacturing partnership addresses recent tariff challenges on imported pharmaceuticals, ensuring domestic production capacity, quality control, and redundancy for cytisinicline drug product.
3. Regulatory and Commercial Timeline
Following an OAI classification at its previous third-party facility unrelated to cytisinicline, Achieve anticipates a Complete Response Letter by June 20, 2026, will resubmit the NDA naming Adare in Q4 2026, and aims for a first-half 2027 product launch.